


# Washington

Bristol Myers Squibb's presence in Washington state is pivotal to our vision of transforming patients' lives through science. Our teams in **Bothell** and **Seattle** discover, develop, manufacture and commercialize therapies in immuno-oncology and cell therapy. We operate with the entrepreneurial spirit of a biotech start-up combined with the expertise, resources, infrastructure and global scale of a leading biopharma to advance novel treatments with precision and purpose for people with cancer.



## Areas of Focus

**Seattle** is home to the Immuno-Oncology and Cell Therapy Thematic Research Center, a fundamental research and early development engine for **engineered cell-based therapies and biotherapeutics** aimed at investigating novel ways to precisely address cancer-specific vulnerabilities and enhance or restore the body's ability to eliminate cancer. Cell Therapy Development and Operations teams, also based in Seattle, focus on developing the technologies and manufacturing platforms used to produce, test and deliver innovative cell therapy medicines in early-stage clinical and commercial settings.

**Bothell's state-of-the-art cell therapy manufacturing facility** is equipped with cutting-edge technologies and highly trained manufacturing teams to produce engineered cell-based therapies for people with cancer. As the first Bristol Myers Squibb cell therapy manufacturing facility in operation, process innovations initiated by our teams have given rise to some of our newest technologies and manufacturing strategies being deployed across our growing global network of cell therapy manufacturing facilities.

## Scientific and Corporate Investments

### Jobs

Bristol Myers Squibb provides high-quality jobs for residents across the state and currently employs approximately 1,530 employees\* in Washington state, with a total payroll of \$298.8 million.

\*As of December 2022

### Investments

In 2022, economic investment in a wide range of local businesses through vendor relationships totaled \$142.9 million in Washington state, including \$4.9 million in investments with diverse vendors.

### Clinical Trials

Bristol Myers Squibb conducted activities to support 112 clinical trials across 182 study sites in Washington state in 2022.

## Making a Difference at Work and in the Community

**Our commitment to Washington state means working to support and strengthen the communities in which we work and live.**



### Local Community Support

We support programs, initiatives and organizations such as Compass Housing Alliance, Life Science Washington Institute, the Museum of Flight, Pacific Science Center, the Northshore Schools Foundation and Shoreline Community College that help improve health, promote STEM education and deliver basic human services to our communities.



### Corporate and Community Giving

In 2022, we delivered more than \$765,000 in giving and sponsorship support to a range of local organizations and programs serving communities in Washington state.



### Global Inclusion and Diversity

Bristol Myers Squibb has made measurable progress against its goal to award \$150 million to address health disparities: Nearly \$100 million in distributed funding has reached more than 10 million people through programs and services.

Bristol Myers Squibb is announcing \$10 million in grants during 2023 to 17 U.S. organizations focused on addressing social determinants of health, including healthcare access and literacy to help close gaps and increase access to healthcare.

We believe that these commitments will help improve outcomes and transform the lives of patients and communities in the United States and globally.



### Protecting the Environment

As we experienced significant business growth, our company also has been able to reduce operation-generated greenhouse gas emissions by more than 20% and water use by more than 10% over our 2015 baselines. We are committed to running on 100% renewable electricity by 2030.